ETERNAL's third newsletter features two important positioning papers from the ETERNAL stable: a concept paper laying out the key-drivers and a possible regulatory roadmap for “compliant-by-design” pharmaceutical strategies on the one hand, and a review of current and future EMA regulation covering the environmental risk assessment of pharmaceuticals complete with areas where these could be strengthened, improved and gaps filled. You can also read about some of our plans for conferences and workshops in the first half of 2024.
This site uses cookies that enable us to make improvements, provide relevant content, and for analytics purposes. For more details, see our Cookie Policy.
By clicking Accept, you consent to our use of cookies.
